Agitation: Clinical Trials

1 active not recruiting. 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	1	Active not recruiting 1

Follow Agitation: new trials by email Literature Review of Agitation trials Research Report on Agitation

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Masupirdine 50 mg, Masupirdine 100 mg, Placebo - Agitation, Alzheimer's Type Dementia	Phase 3	Active not recruiting	Suven Life Sciences Limited	375	2022-11-01	2026-09-15

Narrower conditions

Psychomotor Agitation (1)

Broader conditions

Aberrant Motor Behavior in Dementia (1)  ·  Behavior (1)  ·  Behavioral Symptoms (1)  ·  Dyskinesias (1)  ·  Nervous System Diseases (1)  ·  Neurobehavioral Manifestations (1)  ·  Neurologic Manifestations (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Psychomotor Disorders (1)  ·  Signs and Symptoms (1)

Interventions

1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate (1)

Sponsors

Suven Life Sciences Limited (1)

Countries

Croatia (1)  ·  Poland (1)  ·  Serbia (1)  ·  United States (1)